Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes

ClinicalTrials.gov ID: NCT00982228

Public ClinicalTrials.gov record NCT00982228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

NN1250-3583: A 52 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Parallel, Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (BEGIN™: BB T1 LONG) / NN1250-3644: An Extension Trial to Trial NN1250-3583 Comparing Safety and Efficacy of NN1250 With Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin, in Type 1 Diabetes (BEGIN™: T1)

Study identification

NCT ID
NCT00982228
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
629 participants

Conditions and interventions

Interventions

  • insulin aspart Drug
  • insulin degludec Drug
  • insulin glargine Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2009
Primary completion
Nov 7, 2010
Completion
Nov 7, 2010
Last update posted
Apr 5, 2017

2009 – 2010

United States locations

U.S. sites
59
U.S. states
31
U.S. cities
52
Facility City State ZIP Site status
Novo Nordisk Investigational Site Birmingham Alabama 35209
Novo Nordisk Investigational Site Huntsville Alabama 35801
Novo Nordisk Investigational Site Peoria Arizona 85381
Novo Nordisk Investigational Site Concord California 94520
Novo Nordisk Investigational Site Fresno California 93720
Novo Nordisk Investigational Site Greenbrae California 94904
Novo Nordisk Investigational Site Huntington Beach California 92648
Novo Nordisk Investigational Site La Mesa California 91942
Novo Nordisk Investigational Site Los Gatos California 95032
Novo Nordisk Investigational Site Santa Barbara California 93105
Novo Nordisk Investigational Site Tustin California 92780
Novo Nordisk Investigational Site Ventura California 93003
Novo Nordisk Investigational Site Walnut Creek California 94598-3347
Novo Nordisk Investigational Site Aurora Colorado 80045-7402
Novo Nordisk Investigational Site Aurora Colorado 80045
Novo Nordisk Investigational Site Hollywood Florida 33021
Novo Nordisk Investigational Site Lake Mary Florida 32746
Novo Nordisk Investigational Site Miami Florida 33136
Novo Nordisk Investigational Site Atlanta Georgia 30318
Novo Nordisk Investigational Site Lawrenceville Georgia 30046
Novo Nordisk Investigational Site Honolulu Hawaii 96814
Novo Nordisk Investigational Site Chicago Illinois 60611-2661
Novo Nordisk Investigational Site Vincennes Indiana 47591-1029
Novo Nordisk Investigational Site Lexington Kentucky 40503
Novo Nordisk Investigational Site Lexington Kentucky 40536-0284
Novo Nordisk Investigational Site Scarborough Maine 04074-9302
Novo Nordisk Investigational Site Hyattsville Maryland 20782
Novo Nordisk Investigational Site Rockville Maryland 20852
Novo Nordisk Investigational Site Brockton Massachusetts 02301
Novo Nordisk Investigational Site Flint Michigan 48503-5904
Novo Nordisk Investigational Site Livonia Michigan 48154
Novo Nordisk Investigational Site Eagan Minnesota 55123
Novo Nordisk Investigational Site Chesterfield Missouri 63017
Novo Nordisk Investigational Site Jefferson City Missouri 65109
Novo Nordisk Investigational Site Saint Charles Missouri 63303
Novo Nordisk Investigational Site Great Falls Montana 59405
Novo Nordisk Investigational Site Omaha Nebraska 68114
Novo Nordisk Investigational Site Omaha Nebraska 68124
Novo Nordisk Investigational Site Dover New Hampshire 03820
Novo Nordisk Investigational Site Lawrenceville New Jersey 08648
Novo Nordisk Investigational Site Flushing New York 11365
Novo Nordisk Investigational Site Rochester New York 14607
Novo Nordisk Investigational Site Chapel Hill North Carolina 27517
Novo Nordisk Investigational Site Raleigh North Carolina 27609
Novo Nordisk Investigational Site Columbus Ohio 43203
Novo Nordisk Investigational Site Oklahoma City Oklahoma 73104
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15212
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15224-2215
Novo Nordisk Investigational Site Rapid City South Dakota 57701
Novo Nordisk Investigational Site Chattanooga Tennessee 37404
Novo Nordisk Investigational Site Chattanooga Tennessee 37411
Novo Nordisk Investigational Site Dallas Texas 75230
Novo Nordisk Investigational Site Dallas Texas 75231
Novo Nordisk Investigational Site Dallas Texas 75246
Novo Nordisk Investigational Site Lubbock Texas 79423
Novo Nordisk Investigational Site Round Rock Texas 78681
Novo Nordisk Investigational Site St. George Utah 84790
Novo Nordisk Investigational Site Renton Washington 98057
Novo Nordisk Investigational Site Milwaukee Wisconsin 53209

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00982228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 5, 2017 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00982228 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →